Skip to main content
Clinical Trials/CTRI/2023/01/048849
CTRI/2023/01/048849
Completed
未知

A retrospective study to evaluate efficacy and safety of oral tofacitinib in vitiligo and its variants

A0 sites40 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
A
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 23, 2023
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
A

Eligibility Criteria

Inclusion Criteria

  • 1\. All clinically diagnosed cases of different variants of vitiligo
  • 2\.Patients who were started on oral tofacitinib for vitiligo

Exclusion Criteria

  • Patients receiving other systemic immunosuppressive drugs

Outcomes

Primary Outcomes

Not specified

Similar Trials